Extensively Drug-Resistant Tuberculosis in South Korea: Risk Factors and Treatment Outcomes among Patients at a Tertiary Referral Hospital
Open Access
- 1 January 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 46 (1), 42-49
- https://doi.org/10.1086/524017
Abstract
Background. Extensively drug‐resistant (XDR) tuberculosis (TB) is a major public health threat in South Korea. Methods. We analyzed baseline epidemiological data for 250 patients enrolled in an ongoing prospective observational study of TB at a large tertiary referral hospital in South Korea. Results. Twenty‐six subjects with XDR TB were identified; all were patients who had previously received TB therapy. Cumulative previous treatment duration (range, 18–34 months; odds ratio [OR], 5.6; 95% confidence interval [CI], 1.0–59), number of previously received second‐line anti‐TB drugs (OR, 1.3; 95% CI, 1.1–1.5), and female sex (OR, 3.2; 95% CI, 1.1–8.3) were significantly associated with XDR TB in crude analyses. After controlling for other factors in a multivariable model, cumulative previous treatment duration remained significantly associated with XDR TB (OR, 5.8; 95% CI, 1.0–61). Subjects with XDR TB were more likely to produce culture‐positive sputum at 6 months, compared with patients with non—multidrug resistant TB (risk ratio, 13; 95% CI, 5.1–53). Kanamycin resistance was found to be predictive of 6‐month culture positivity after adjustment for ofloxacin and streptomycin resistance (risk ratio, 3.9; 95% CI, 1.9–11). Conclusions. XDR TB was found to be associated with the cumulative duration of previous treatment with second‐line TB drugs among subjects in a tertiary care TB hospital. Patients with XDR TB were more likely to not respond to therapy, and successful conversion of sputum culture results to negative was correlated with initial susceptibility to both fluoroquinolones and kanamycin but not to streptomycin.This publication has 9 references indexed in Scilit:
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaThe Lancet, 2006
- Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areasThorax, 2006
- Extensively Drug‐Resistant Tuberculosis: 2 Years of Surveillance in IranClinical Infectious Diseases, 2006
- Antibiotic use following a Korean national policy to prohibit medication dispensing by physiciansHealth Policy and Planning, 2005
- Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort studyThe Lancet, 2005
- DOTS-Plus for multidrug-resistant tuberculosis in the Philippines: global assistance urgently neededTuberculosis, 2003
- In Vitro Activities of Fourteen Antimicrobial Agents Against Drug Susceptible and Resistant Clinical Isolates of Mycobacterium tuberculosis and Comparative Intracellular Activities Against the Virulent H37Rv Strain in Human MacrophagesCurrent Microbiology, 1996
- Clinical Pharmacokinetics of the Antituberculosis DrugsClinical Pharmacokinetics, 1984
- Pharmacokinetics of Aminoglycosides in Subjects with Normal and Impaired Renal FunctionAntibiotics and chemotherapy, 1977